Market Overview:
The global diabetic macular edema drug market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The increasing prevalence of diabetes, rising geriatric population, and technological advancements are some of the major factors that are driving the growth of this market. The intravitreal injections segment is expected to dominate the market during the forecast period owing to their high efficacy and safety profile. However, the intravitreal implants segment is projected to grow at a higher CAGR during the forecast period due to their advantages such as long-term efficacy and lower incidence of adverse effects as compared with intravitreal injections. The anti-VEGF drugs segment is expected to account for a major share of this market in 2018 owing to their high efficiency in treating diabetic macular edema (DME).
Product Definition:
A drug used to treat diabetic macular edema, a complication of diabetes that can lead to vision loss. The drug is injected into the eye and works by reducing the leaking of fluid from blood vessels in the retina.
Intravitreal Injections:
Intravitreal injections are used for the treatment of diabetic macular edema. The drug is manufactured by Novartis AG and was approved by FDA in 2011. It is a long-lasting injectable that reduces the swelling caused due to high blood sugar in patients suffering from diabetes mellitus.
Intravitreal Implants:
Intravitreal implants are used for the treatment of diabetic macular edema. The drug is currently under phase III clinical trials and has received FDA approval in July 2015 as a single-injection therapy to treat diabetic macular edema.
Application Insights:
On the basis of application, the global market is segmented into anti-VEGF therapy, corticosteroids, insulin and other antidiabetic drugs, glaucoma medicines and others. The use of anti-VEGF therapies was observed to be higher in various regions including North America and Europe. This can be attributed to increasing prevalence of VEGF gene mutations that lead to increased production of VEGF which in turn causes diabetic retinopathy.
The use of glucocorticoids is observed to be highest in Asia Pacific region due largely to high incidence rate of asthma as well as other respiratory diseases prevalent across this region. Moreover, increasing awareness about these drugs among healthcare professionals will boost industry growth over the forecast period especially during 2020s till 2030 resulting in lucrative revenue for manufacturers from 2019 onward.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the local presence of major players, high disposable income, and availability of effective treatment methods for DME. In addition, increasing prevalence of diabetes is also expected to fuel regional growth during the forecast period. Asia Pacific region is anticipated to witness lucrative CAGR over the forecast period owing to rising geriatric population base and growing awareness about early diagnosis & treatment methods for DME. Moreover Diabetic retinopathy affects more than 60 million people in China making it one of the leading causes of blindness there (source: WHO).
Key players operating in this industry include Bausch & Lomb; Eye Care Pharmaceuticals Inc.; Novartis AG; Pfizer Inc.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is expected to drive the demand for diabetic macular edema drugs in the coming years.
- Growing awareness about diabetic macular edema: There is a growing awareness about diabetic macular edema among people with diabetes and healthcare professionals alike. This is likely to boost the demand for DMED drugs in the near future.
- Technological advancements: The development of novel DMED drugs and therapies has been spurred by technological advancements in recent years. This is likely to result in increased adoption of these treatments, driving market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetic Macular Edema Drug Market Research Report
By Type
Intravitreal Injections, Intravitreal Implants
By Application
Anti-VEGF, Corticosteroids, Others
By Companies
Novartis, Bayer, Allergan, Hoffman-La Roche, Alimera, Valeant, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Diabetic Macular Edema Drug Market Report Segments:
The global Diabetic Macular Edema Drug market is segmented on the basis of:
Types
Intravitreal Injections, Intravitreal Implants
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anti-VEGF, Corticosteroids, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Bayer
- Allergan
- Hoffman-La Roche
- Alimera
- Valeant
- Novartis
Highlights of The Diabetic Macular Edema Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Intravitreal Injections
- Intravitreal Implants
- By Application:
- Anti-VEGF
- Corticosteroids
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetic Macular Edema Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diabetic macular edema drug is a medication used to treat diabetic macular edema. It works by reducing swelling and inflammation in the eyes caused by the condition.
Some of the key players operating in the diabetic macular edema drug market are Novartis, Bayer, Allergan, Hoffman-La Roche, Alimera, Valeant, Novartis.
The diabetic macular edema drug market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Diabetic Macular Edema Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Diabetic Macular Edema Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Diabetic Macular Edema Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Diabetic Macular Edema Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Diabetic Macular Edema Drug Market Size & Forecast, 2020-2028
4.5.1 Diabetic Macular Edema Drug Market Size and Y-o-Y Growth
4.5.2 Diabetic Macular Edema Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Intravitreal Injections
5.2.2 Intravitreal Implants
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Anti-VEGF
6.2.2 Corticosteroids
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Diabetic Macular Edema Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Diabetic Macular Edema Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Intravitreal Injections
9.6.2 Intravitreal Implants
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Anti-VEGF
9.10.2 Corticosteroids
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Intravitreal Injections
10.6.2 Intravitreal Implants
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Anti-VEGF
10.10.2 Corticosteroids
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Intravitreal Injections
11.6.2 Intravitreal Implants
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Anti-VEGF
11.10.2 Corticosteroids
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Intravitreal Injections
12.6.2 Intravitreal Implants
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Anti-VEGF
12.10.2 Corticosteroids
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Intravitreal Injections
13.6.2 Intravitreal Implants
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Anti-VEGF
13.10.2 Corticosteroids
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Diabetic Macular Edema Drug Market: Competitive Dashboard
14.2 Global Diabetic Macular Edema Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Bayer
14.3.3 Allergan
14.3.4 Hoffman-La Roche
14.3.5 Alimera
14.3.6 Valeant
14.3.7 Novartis
